Alphatec Holdings, Inc. (NASDAQ:ATEC) Shares Sold by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company decreased its holdings in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) by 3.2% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 56,388 shares of the medical technology company’s stock after selling 1,869 shares during the period. The Manufacturers Life Insurance Company’s holdings in Alphatec were worth $314,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Magnetar Financial LLC acquired a new stake in shares of Alphatec during the second quarter worth about $10,957,000. First Eagle Investment Management LLC acquired a new stake in shares of Alphatec during the second quarter worth about $1,071,000. Lighthouse Investment Partners LLC boosted its stake in shares of Alphatec by 257.5% during the second quarter. Lighthouse Investment Partners LLC now owns 208,594 shares of the medical technology company’s stock worth $2,180,000 after buying an additional 150,244 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its stake in shares of Alphatec by 11.3% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,928,094 shares of the medical technology company’s stock worth $16,280,000 after buying an additional 297,850 shares during the period. Finally, AlphaCentric Advisors LLC acquired a new stake in shares of Alphatec during the third quarter worth about $2,057,000. Institutional investors and hedge funds own 66.35% of the company’s stock.

Alphatec Trading Down 0.8 %

Shares of Alphatec stock opened at $9.62 on Monday. Alphatec Holdings, Inc. has a 12-month low of $4.88 and a 12-month high of $17.34. The company has a current ratio of 2.32, a quick ratio of 1.15 and a debt-to-equity ratio of 30.21. The stock has a market cap of $1.36 billion, a PE ratio of -7.52 and a beta of 1.38. The company has a 50-day moving average of $7.98 and a two-hundred day moving average of $8.12.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of Alphatec in a research note on Thursday, October 31st. Barclays increased their price target on shares of Alphatec from $19.00 to $20.00 and gave the stock an “overweight” rating in a report on Tuesday, November 19th. Needham & Company LLC reissued a “buy” rating and set a $13.00 price target on shares of Alphatec in a report on Thursday, October 31st. Lake Street Capital cut their price target on shares of Alphatec from $32.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, September 3rd. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $20.00 price target on shares of Alphatec in a report on Friday, August 30th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, Alphatec has a consensus rating of “Moderate Buy” and an average price target of $17.11.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.